Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03351114 · ClinicalTrials.gov registry record · Phase 2
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
A Phase 2 study of Morphea, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03351114 is a Phase 2 study of Morphea that has completed, run by Duke University. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03351114, a Phase 2 study of Morphea, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
Conditions Studied
Interventions
- DRUG Crisaborole
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2020-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03351114
The ClinicalTrials.gov registry entry for NCT03351114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Morphea appearing as the primary indexed condition, and to 1 intervention - of which Crisaborole is the first listed.
NCT03351114 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03351114 about?
NCT03351114 is a clinical study titled "Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea". This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
What is the current status of trial NCT03351114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-09-01. Estimated completion is 2020-03-10.
What conditions does trial NCT03351114 study?
This clinical trial studies the following conditions: Morphea.
What interventions are being tested in trial NCT03351114?
The interventions under investigation include: Crisaborole (DRUG).
Who is sponsoring clinical trial NCT03351114?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03351114 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Morphea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.